

**Oklahoma Health Care Authority
Drug Utilization Review Board
(DUR Board)
Meeting – February 12, 2014 @ 6:00 p.m.**

Oklahoma Health Care Authority
2401 N.W. 23rd Street, Suite 1-A
Oklahoma City, Oklahoma 73107
Ponca Room (North Entrance)

AGENDA

Discussion and Action on the Following Items:

Items to be presented by Dr. Muchmore, Chairman:

1. Call To Order

- A. Roll Call – Dr. Cothran

Items to be presented by Dr. Muchmore, Chairman:

2. Public Comment Forum

- A. Acknowledgment of Speakers and Agenda Items

Items to be presented by Dr. Muchmore, Chairman:

3. Action Item – Approval of DUR Board Meeting Minutes – See Appendix A

- A. December 11, 2013 DUR Minutes – Vote
- B. December 11, 2013 DUR Recommendation Memorandum
- C. Correspondence

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

4. Update on DUR/ Medication Coverage Authorization Unit, SoonerPsych Program Update – See Appendix B

- A. Medication Coverage Activity for January 2014
- B. Pharmacy Help Desk Activity for January 2014
- C. SoonerPsych Program Update

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman:

5. Action Item – Vote to Prior Authorize Procysbi™ (Cysteamine Bitartrate) – See Appendix C

- A. COP Recommendations

Items to be presented by Dr. Adams, Dr. Muchmore, Chairman

6. Action Item – Vote to Prior Authorize Ravicti® (Glycerol Phenylbutyrate) – See Appendix D

- A. COP Recommendations

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

7. Action Item – Vote to Prior Authorize Sirturo™ (Bedaquiline Fumarate) – See Appendix E

- A. COP Recommendations

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

8. Action Item – Vote to Prior Authorize Inhaled Tobramycin Products and Pulmozyme® (Dornase Alfa) – See Appendix F

- A. COP Recommendations

Items to be presented by Dr. Nawaz, Dr. Muchmore, Chairman

- 9. Drug Utilization Review of Pulmonary Arterial Hypertension Medications and 30 Day Notice to Prior Authorize Adempas® (Riociguat) and Opsumit® (Macitentan) – Appendix G**
 - A. Introduction
 - B. Current Authorization Criteria
 - C. Utilization Details
 - D. Prior Authorization
 - E. Market News and Updates
 - F. COP Recommendations
 - G. Utilization Details
 - H. Product Details of Adempas®
 - I. Product Details of Opsumit®

Items to be presented by Dr. Le, Dr. Muchmore, Chairman

- 10. Drug Utilization Review of Cephalosporin Antibiotics and 30 Day Notice to Prior Authorize Select Cephalosporins – See Appendix H**
 - A. Introduction
 - B. Utilization
 - C. COP Recommendations
 - D. Utilization Details

Items to be presented by Dr. Holderread, Dr. Muchmore, Chairman

- 11. Drug Utilization Review of Ophthalmic Anti-Inflammatory Medications – See Appendix I**
 - A. Introduction
 - B. Utilization
 - C. Market News and Updates
 - D. COP Recommendations

Items to be presented by Dr. Cothran, Dr. Muchmore, Chairman

- 12. FDA and DEA Updates – See Appendix J**

- 13. Future Business**

- A. Annual Reviews
- B. New Product Reviews

- 14. Adjournment**